| Drug ID: | Drug143 |
|---|---|
| Drug Name: | Minocycline |
| CID: | 54675783 |
| DrugBank ID: | DB01017 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT06201793 |
| Molecular Formula: | C23H27N3O7 |
| Molecular Weight: | 457.5 g/mol |
| Isomeric SMILES: | CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C |
| Synonyms: | minocycline; 10118-90-8; Minocyclin; Minociclina; CL 59806; Minocyn; 7-Dimethylamino-6-demethyl-6-deoxytetracycline; (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE; CHEBI:50694; FYY3R43WGO |
| Phase 0: | 3 |
| Phase 1: | 58 |
| Phase 2: | 105 |
| Phase 3: | 40 |
| Phase 4: | 52 |
| Description: | A tetracycline analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant staphylococcus infections. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1138 | 54675783 | Minocycline | 949000 | rpsI | Escherichia coli K-12 | 14723559 | Inhibitor |
| dt1139 | 54675783 | Minocycline | 947793 | rpsD | Escherichia coli K-12 | 14723559 | Inhibitor |
| dt1140 | 54675783 | Minocycline | 3553 | IL1B | Homo sapiens (human) | Modulator | |
| dt1141 | 54675783 | Minocycline | 240 | ALOX5 | Homo sapiens (human) | Inhibitor | |
| dt1142 | 54675783 | Minocycline | 4318 | MMP9 | Homo sapiens (human) | Inhibitor | |
| dt1143 | 54675783 | Minocycline | 7422 | VEGFA | Homo sapiens (human) | Inhibitor | |
| dt1144 | 54675783 | Minocycline | 834 | CASP1 | Homo sapiens (human) | Negative modulator | |
| dt1145 | 54675783 | Minocycline | 836 | CASP3 | Homo sapiens (human) | Negative modulator | |
| dt1146 | 54675783 | Minocycline | 54205 | CYCS | Homo sapiens (human) | Negative modulator | |
| dt1147 | 54675783 | Minocycline | 5594 | MAPK1 | Homo sapiens (human) | 11986668 | Inhibitor |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06201793 | Minocyclin in Ulcerative Colitis as Added on Therapy | PHASE2 | RECRUITING | Mostafa Bahaa | Inflammatory Bowel Diseases | DRUG: Mesalazine|DRUG: Minocycline | Details |
| NCT00820365 | SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease | PHASE2 | COMPLETED | 4SC AG | Inflammatory Bowel Disease (IBD) | DRUG: SC12267 (4SC-101) | Details |
| NCT05986136 | Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease | PHASE2|PHASE3 | RECRUITING | Mostafa Bahaa | Inflammatory Bowel Diseases | DRUG: Mesalamine|DRUG: Dapagliflozin 10mg Tab | Details |
| NCT00207688 | A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients | None | COMPLETED | Janssen Research & Development, LLC | Ulcerative Colitis | DRUG: Infliximab 5 mg/kg|DRUG: Infliximab 10 mg/k… | Details |
| NCT02611830 | Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis | PHASE3 | COMPLETED | Takeda | Colitis, Ulcerative | DRUG: Vedolizumab 300 mg IV|DRUG: Placebo IV|DRUG… | Details |
| NCT05907330 | Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis | PHASE2 | NOT_YET_RECRUITING | Curacle Co., Ltd. | Ulcerative Colitis | DRUG: CU104|DRUG: Placebo | Details |
| NCT05076175 | A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis | PHASE2|PHASE3 | RECRUITING | Bristol-Myers Squibb | Colitis, Ulcerative | DRUG: Ozanimod | Details |
| NCT06281704 | A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis | PHASE1 | COMPLETED | Akeso | Ulcerative Colitis | BIOLOGICAL: AK101 IV|BIOLOGICAL: AK101 SC|BIOLOGI… | Details |
| NCT06582264 | A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis | PHASE1 | RECRUITING | Microbiotica Ltd | Ulcerative Colitis | BIOLOGICAL: MB310|OTHER: Placebo|DRUG: Vancomycin | Details |
| NCT01039597 | Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis | PHASE1|PHASE2 | UNKNOWN | Ore Pharmaceuticals, Inc. | Mild to Moderate Ulcerative Colitis | DRUG: ORE1001|DRUG: Placebo | Details |
| NCT02246686 | Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients | PHASE2 | TERMINATED | Bayer | Colitis, Ulcerative | DRUG: STW5-II (Iberogast N, BAY98-7410)|DRUG: Pla… | Details |
| NCT00295282 | A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis | PHASE1 | COMPLETED | Bristol-Myers Squibb | Ulcerative Colitis | DRUG: MDX-1100 (anti-CXCL10 human monoclonal anti… | Details |
| NCT00656890 | A Study of MDX-1100 in Subjects With Active Ulcerative Colitis | PHASE2 | COMPLETED | Bristol-Myers Squibb | Ulcerative Colitis | BIOLOGICAL: sterile saline for injection|BIOLOGIC… | Details |
| NCT01216280 | Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis | PHASE2 | UNKNOWN | Natrogen Therapeutics International, Inc | Ulcerative Colitis | DRUG: placebo capsule|DRUG: 10 mg Natura-alpha ca… | Details |
| NCT04209556 | A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis | PHASE2 | WITHDRAWN | Pfizer | Ulcerative Colitis | DRUG: PF-06826647 100 mg QD|DRUG: PF-06826647 300… | Details |
| NCT00487539 | An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis | PHASE2|PHASE3 | COMPLETED | Janssen Research & Development, LLC | Colitis, Ulcerative | BIOLOGICAL: Placebo|BIOLOGICAL: Golimumab 100 mg|… | Details |
| NCT02435992 | Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis | PHASE3 | COMPLETED | Celgene | Ulcerative Colitis | DRUG: RPC1063|DRUG: Placebo | Details |
| NCT02531126 | An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis | PHASE3 | COMPLETED | Celgene | Ulcerative Colitis | DRUG: RPC1063 | Details |
| NCT06663605 | Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients. | PHASE1 | RECRUITING | Palisade Bio | Ulcerative Colitis (UC)|Healthy Volunteer | DRUG: PALI-2108|DRUG: PALI-2108 Placebo | Details |
| NCT03760003 | Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis | PHASE2 | COMPLETED | Abivax S.A. | Ulcerative Colitis | DRUG: ABX464 25mg|DRUG: ABX464 50mg|DRUG: ABX464 … | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S06 | Anti-fibrosis | fibrosis; tissue remodelling | GS-5745; STNM01 | Tissue remodelling and destruction in patients with IBD is … | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
Minocycline Prevents the Development of Key Features of Inflammation and Pain i…
PMID: 36183969
Year: 2023
Relationship Type:
Treatment
Score: 9.5
Abdominal pain is a common feature in inflammatory bowel disease (IBD) patients, and greatly compromises their quality of life. Therefore, the identi…
Minocycline: far beyond an antibiotic
PMID: 23441623
Year: 2013
Relationship Type:
Treatment
Score: 9.1
Minocycline is a second-generation, semi-synthetic tetracycline that has been in therapeutic use for over 30 years because of its antibiotic properti…
The intestinal anti-inflammatory effect of minocycline in experimental colitis …
PMID: 21193045
Year: 2011
Relationship Type:
Treatment
Score: 6.1
Comment in Inflamm Bowel Dis. 2011 Aug;17(8):1824. BACKGROUND: Reactivation of latent Mycobacterium tuberculosis (TB) is a rare, yet devastatin…